Results 101 to 110 of about 366,020 (324)

Genomic biomarkers in prostate cancer. [PDF]

, 2018
Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer.
Cooperberg, Matthew R, Feng, Felix Y, Kornberg, Zachary, Spratt, Daniel E   +3 more
core  

A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature [PDF]

, 2019
Within five to ten years after radical prostatectomy (RP), approximately 15-34% of prostate cancer (PCa) patients experience biochemical recurrence (BCR), which is defined as recurrence of serum levels of prostate-specific antigen >0.2 µg/L, indicating ...
Erbersdobler, Andreas, Fendler, Annika, Jung, Klaus, Jung, Monika, Kilic, Ergin, Lein, Michael, Stephan, Carsten, Weickmann, Sabine, Zhao, Zhongwei   +8 more
core   +2 more sources

Phase‐Separation of YAP Mediates AJUBA Super Enhancer Activation to Promote Aberrant Mitosis in Breast Cancer

Advanced Science, EarlyView.
YAP undergoes phase separation to activate the AJUBA super‐enhancer, driving aberrant mitosis through spindle checkpoint dysregulation in breast cancer. This study uncovers a mechanistic link between YAP condensates, super‐enhancer activation, and aneuploidy formation.
Rui Zhang, Qingwen Huang, Zhuo Chen, Weijian Meng, Hongliang Dong, Zhihong Qi, Liang Liu, Jie Shen, Daxing Xie   +8 more
wiley   +1 more source

Comparison of the Diagnostic Performance of Multiparametric Prostate Magnetic Resonance Imaging Results with Classical Parameters for Prostate Carcinoma in Gray Zone Patients

Journal of Urological Surgery
Objective: To compare the diagnostic value of prostate imaging-reporting and data system (mpMRI) version 2.0 with classical parameters for prostate cancer detection in gray zone patients with ultrasonography-guided prostate biopsy as a reference point ...
Coşkun Bostancı, Demirhan Örsan Demir
doaj   +1 more source

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1

Asian Journal of Andrology, 2015
Percent free prostatic-specific antigen (%fPSA) has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng ml−1 , however, it remains controversial whether %fPSA is effective in PSA range of 10.1-20.0 ng
Rui Chen, Li-Qun Zhou, Xiao-Bing Cai, Li-Ping Xie, Yi-Ran Huang, Da-Lin He, Xu Gao, Chuan-Liang Xu, Qiang Ding, Qiang Wei, Chang-Jun Yin, Shan-Cheng Ren, Fu-Bo Wang, Ye Tian, Zhong-Quan Sun, Qiang Fu, Lu-Lin Ma, Jun-Hua Zheng, Zhang-Qun Ye, Ding-Wei Ye, Dan-Feng Xu, Jian-Quan Hou, Ke-Xin Xu, Jian-Lin Yuan, Xin Gao, Chun-Xiao Liu, Tie-Jun Pan, Ying-Hao Sun, on behalf of Chinese Prostate Cancer Consortium   +28 more
doaj   +1 more source

Optimal use of prostate specific antigen for prostate cancer screening [PDF]

, 2013
nem
Bojanić Nebojša, Bumbaširević Uroš, Milojević Bogomir, Miočinović Ranko, Stephenson Andrew J., Tulić Cane, Đorđević Miroslav L.   +6 more
core   +1 more source

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

Advanced Science, EarlyView.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu   +15 more
wiley   +1 more source

Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil

BMC Urology
Background Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes.
Juan Manuel Palacios, Pratiksha Kapse, Vanessa Cortes, Marcio Augusto Averbeck, Alberto Budia Alba, Suryakant Somvanshi, Danilo Souza Lima da Costa Cruz, Fiona Pereira   +7 more
doaj   +1 more source

Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness

Tumor Biology, 2019
Prostate cancer represents a major cause of cancer death in men worldwide. Novel non-invasive methods are still required for differentiation of non-aggressive from aggressive tumors.
Robert Lang, Vinzent Rolny, Andreas Leinenbach, Johann Karl, Magdalena Swiatek-de Lange, Uwe Kobold, Mark Schrader, Hans Krause, Markus Mueller, Michael Vogeser   +9 more
doaj   +1 more source

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide

BMC Research Notes, 2018
Objective The objective of this retrospective study was to evaluate whether the effect of second-line therapy of flutamide after bicalutamide can predict the response to abiraterone.
Yasushi Nakai, Nobumichi Tanaka, Makito Miyake, Takeshi Inoue, Satoshi Anai, Kiyohide Fujimoto   +5 more
doaj   +1 more source